$DWTX
Dogwood Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022003885 Filed on March 18, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.269M $4.845M $6.390M
YoY Change -80.14% -50.61% 2266.67%
% of Gross Profit
Research & Development $2.918M $10.80M $30.00K
YoY Change 9628.03% 5464.41% -90.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.188M $15.64M $6.420M
YoY Change -34.77% 56.33% 1026.32%
Operating Profit -$15.64M
YoY Change 56.33%
Interest Expense -$323.7K -$319.3K -$80.00K
YoY Change 304.68% -15.97% 14.29%
% of Operating Profit
Other Income/Expense, Net -$319.3K $0.00
YoY Change -6.36%
Pretax Income -$4.511M -$15.96M -$6.500M
YoY Change -30.6% 54.26% 915.63%
Income Tax
% Of Pretax Income
Net Earnings -$4.511M -$15.96M -$6.500M
YoY Change -30.6% 54.26% 915.63%
Net Earnings / Revenue
Basic Earnings Per Share -$1.92
Diluted Earnings Per Share -$541.5K -$1.92 -$668.7K
COMMON SHARES
Basic Shares Outstanding 8.330M 8.329M
Diluted Shares Outstanding 8.329M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.01M $14.01M $29.80M
YoY Change -52.99% -52.99%
Cash & Equivalents $14.01M $29.80M
Short-Term Investments
Other Short-Term Assets $1.769M $1.769M $1.680M
YoY Change 5.27% 5.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.78M $15.78M $31.47M
YoY Change -49.87% -49.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $15.78M $15.78M $31.47M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $15.78M $15.78M $31.47M
YoY Change -49.87% -49.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $353.9K $353.9K $368.9K
YoY Change -4.08% -4.36%
Accrued Expenses $921.8K $921.8K $784.1K
YoY Change 17.56% -20.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.276M $1.276M $1.532M
YoY Change -16.73% -16.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.276M $1.276M $1.532M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.276M $1.276M $1.532M
YoY Change -16.73% -16.63%
SHAREHOLDERS EQUITY
Retained Earnings -$43.93M -$27.97M
YoY Change 57.07%
Common Stock $833.00 $830.00
YoY Change 0.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.50M $14.50M $29.94M
YoY Change
Total Liabilities & Shareholders Equity $15.78M $15.78M $31.47M
YoY Change -49.87% -49.87%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$4.511M -$15.96M -$6.500M
YoY Change -30.6% 54.26% 915.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.178M -$15.69M -$2.290M
YoY Change 126.12% 302.79% 387.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -97.60K 31.58M
YoY Change -100.0% -100.29% 5440.35%
NET CHANGE
Cash From Operating Activities -5.178M -15.69M -2.290M
Cash From Investing Activities
Cash From Financing Activities 0.000 -97.60K 31.58M
Net Change In Cash -5.178M -15.79M 29.29M
YoY Change -117.68% -153.54% 29190.0%
FREE CASH FLOW
Cash From Operating Activities -$5.178M -$15.69M -$2.290M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8330390
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8329310
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4926985
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Auditor Name
AuditorName
Dixon Hughes Goodman LLP
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
353863
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.10
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001818844
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Registrant Name
EntityRegistrantName
Virios Therapeutics, Inc.
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8305075
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8330390
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8305075
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39811
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
CY2021 dei City Area Code
CityAreaCode
866
CY2021 dei Local Phone Number
LocalPhoneNumber
620-8655
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value per Share
CY2021 dei Trading Symbol
TradingSymbol
VIRI
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
46801675.92
CY2021 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14008184
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29795366
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1768503
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1677365
CY2021Q4 us-gaap Assets Current
AssetsCurrent
15776687
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57905164
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43925373
CY2020Q4 us-gaap Assets Current
AssetsCurrent
31472731
CY2021Q4 us-gaap Assets
Assets
15776687
CY2020Q4 us-gaap Assets
Assets
31472731
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58425604
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
368905
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921760
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
784104
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
378833
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1275623
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1531842
CY2021Q4 us-gaap Liabilities
Liabilities
1275623
CY2020Q4 us-gaap Liabilities
Liabilities
1531842
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8330390
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
833
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
830
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27965105
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29940889
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15776687
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31472731
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10795688
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
194013
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4845252
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9811381
CY2021 us-gaap Operating Expenses
OperatingExpenses
15640940
CY2020 us-gaap Operating Expenses
OperatingExpenses
10005394
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-15640940
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10005394
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5672
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-384222
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
325000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
43221
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-319328
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-341001
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15960268
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10346395
CY2020 us-gaap Partners Capital Account Unit Based Compensation
PartnersCapitalAccountUnitBasedCompensation
2000000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7429518
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29795366
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4926985
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-5017509
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2673800
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15960268
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10346395
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.10
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8329310
CY2020 viri Stock Issued During Period Value Conversion Of Convertible Securities During Corporate Conversion
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesDuringCorporateConversion
3434457
CY2020 viri Partners Capital Account For Accrued Salaries
PartnersCapitalAccountForAccruedSalaries
536880
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31053888
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5429518
CY2020 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
176250
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10346395
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29940889
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
322881
CY2021 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
197562
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15960268
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2021 us-gaap Profit Loss
ProfitLoss
-15960268
CY2020 us-gaap Profit Loss
ProfitLoss
-10346395
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
53983
CY2020 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-15020
CY2020 viri Gain Loss On Vendor Concession
GainLossOnVendorConcession
43221
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
322881
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
91138
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1655829
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
270007
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
51560
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
147773
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
774496
CY2021 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-378833
CY2020 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-144287
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15689578
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3895195
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
-295166
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
31349055
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1994133
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
197562
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
176250
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
63261
CY2020 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
75000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-97604
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33381177
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15787182
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
29485982
CY2021Q1 viri Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
25315
CY2020 viri Amount Of Conversion Of Members Interest Into Common Stock
AmountOfConversionOfMembersInterestIntoCommonStock
21246338
CY2020 viri Amount Of Conversion Of Non Voting Members Interest To Voting Members Interest
AmountOfConversionOfNonVotingMembersInterestToVotingMembersInterest
12601201
CY2021Q1 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
197562
CY2020 viri Payment Of Accrued Salaries Through Issuance Of Members Interest
PaymentOfAccruedSalariesThroughIssuanceOfMembersInterest
536880
CY2021Q4 viri Unamortized Deferred Offering Costs
UnamortizedDeferredOfferingCosts
41445
CY2021Q1 viri Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
78768
CY2021Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2021-01-20
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
309384
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14008184
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29795366
CY2020 us-gaap Interest Paid Net
InterestPaidNet
12551
CY2020 viri Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
295166
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
6108257
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2020Q4 viri Warrants Exercise Price As Percentage Of Initial Public Offering Price
WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice
1.25
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15960268
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10346395
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15689578
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3895195
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43900000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of Credit Risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p>
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
104083
CY2020Q3 viri Employment Agreement Severance Payment Payment Period
EmploymentAgreementSeverancePaymentPaymentPeriod
P1Y
CY2020Q3 viri Employment Agreement Change Of Control Termination Payment Period
EmploymentAgreementChangeOfControlTerminationPaymentPeriod
P45D
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
0
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
0
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
0
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7375
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13548
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921760
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1329385
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1586042
CY2021Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
422591
CY2020Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
85270
CY2021Q4 viri Prepaid Services
PrepaidServices
15664
CY2020Q4 viri Prepaid Services
PrepaidServices
5729
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
863
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
324
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1768503
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1677365
CY2020Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2021Q4 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
138522
CY2021Q4 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
24100
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8992
CY2020Q4 viri Debt Conversion Accrued Interest Paid In Cash
DebtConversionAccruedInterestPaidInCash
9551
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
820033
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105044
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
532678
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
573479
CY2021Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
784104
CY2020Q4 us-gaap Notes Payable
NotesPayable
0
CY2020 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
329998
CY2021Q4 viri Debt Instrument Convertible Interest Conversion Rate Percentage
DebtInstrumentConvertibleInterestConversionRatePercentage
0.25
CY2021 viri Debt Instrument Convertible Interest Warrant Coverage Exercisable Period
DebtInstrumentConvertibleInterestWarrantCoverageExercisablePeriod
P30D
CY2021 viri Debt Instrument Convertible Interest Warrant Coverage Exercisable Period
DebtInstrumentConvertibleInterestWarrantCoverageExercisablePeriod
P30D
CY2021 viri Debt Instrument Convertible Interest Warrant Coverage Exercisable Period
DebtInstrumentConvertibleInterestWarrantCoverageExercisablePeriod
P30D
CY2020Q3 viri Debt Instrument Convertible Interest Warrant Coverage Exercisable Period
DebtInstrumentConvertibleInterestWarrantCoverageExercisablePeriod
P30D
CY2020Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
3279133
CY2020Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
196769
CY2020Q4 viri Unamortized Deferred Offering Costs
UnamortizedDeferredOfferingCosts
41445
CY2020Q4 viri Gain Loss On Conversion Of Convertible Debt
GainLossOnConversionOfConvertibleDebt
0
CY2020Q4 viri Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
961
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
390015
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
428441
CY2021Q3 viri Number Of Membership Interests Issuances Approved By Board
NumberOfMembershipInterestsIssuancesApprovedByBoard
2
CY2020Q3 viri Percentage Of Membership Interests Issuance To Founder Capital Raise
PercentageOfMembershipInterestsIssuanceToFounderCapitalRaise
0.050
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2000000
CY2020Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
3279133
CY2020Q4 viri Debt Conversion Original Debt Accrued Interest
DebtConversionOriginalDebtAccruedInterest
196769
CY2020Q4 viri Unamortized Deferred Offering Costs
UnamortizedDeferredOfferingCosts
41445
CY2020Q4 viri Gain Loss On Conversion Of Convertible Debt
GainLossOnConversionOfConvertibleDebt
0
CY2020Q4 viri Debt Conversion Accrued Interest Paid In Cash
DebtConversionAccruedInterestPaidInCash
9551
CY2020Q4 viri Common And Preferred Stock Shares Authorized
CommonAndPreferredStockSharesAuthorized
45000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021 viri Number Of Votes Per Common Stock
NumberOfVotesPerCommonStock
1
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2021Q4 us-gaap Share Price
SharePrice
10.00
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y11M15D
CY2021 viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2021Q4 viri Aggregate Intrinsic Value Of Warrants Outstanding
AggregateIntrinsicValueOfWarrantsOutstanding
0
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
17956000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 viri Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.0033
CY2020 viri Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.0156
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0447
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0420
CY2021 viri Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Percent
EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent
-0.0182
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0015
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0027
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2347
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2391
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4586488
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
591439
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1338234
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1310207
CY2020Q4 viri Deferred Tax Assets Accrual To Cash Adjustments
DeferredTaxAssetsAccrualToCashAdjustments
314492
CY2021Q4 viri Deferred Tax Assets Investment In Partnership
DeferredTaxAssetsInvestmentInPartnership
30593
CY2020Q4 viri Deferred Tax Assets Investment In Partnership
DeferredTaxAssetsInvestmentInPartnership
31136
CY2021Q4 viri Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
16299
CY2020Q4 viri Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
17467
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5971614
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2264741
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5581599
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1836300
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
390015
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
428441
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
390015
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
428441
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3745299
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1387078
CY2021 dei Auditor Firm
AuditorFirmId
57

Files In Submission

Name View Source Status
0001558370-22-003885-index-headers.html Edgar Link pending
0001558370-22-003885-index.html Edgar Link pending
0001558370-22-003885.txt Edgar Link pending
0001558370-22-003885-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k001.jpg Edgar Link pending
tmb-20211231x10k002.jpg Edgar Link pending
tmb-20211231x10k003.jpg Edgar Link pending
tmb-20211231x10k004.jpg Edgar Link pending
tmb-20211231x10k005.jpg Edgar Link pending
tmb-20211231x10k006.jpg Edgar Link pending
tmb-20211231x10k007.jpg Edgar Link pending
tmb-20211231x10k009.jpg Edgar Link pending
tmb-20211231x10k010.jpg Edgar Link pending
tmb-20211231x10k011.jpg Edgar Link pending
tmb-20211231x10k012.jpg Edgar Link pending
tmb-20211231x10k013.jpg Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex31d2.htm Edgar Link pending
tmb-20211231xex32.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable